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Abstract: Background SARS-CoV-2 infection (COVID-19 disease) can induce systemic vascular involve-
ment contributing to morbidity and mortality. SARS-CoV-2 targets epithelial and endothelial cells
through the ACE2 receptor. The anatomical involvement of the coronary tree is not explored yet.
Methods Cardiac autopsy tissue of the entire coronary tree (main coronary arteries, epicardial arteri-
oles/venules, epicardial capillaries) and epicardial nerves were analyzed in COVID-19 patients (n = 6).
All anatomical regions were immunohistochemically tested for ACE2, TMPRSS2, CD147, CD45, CD3,
CD4, CD8, CD68 and IL-6. COVID-19 negative patients with cardiovascular disease (n = 3) and in-
fluenza A (n = 6) served as controls. • View related content for this article Findings COVID-19 positive
patients showed strong ACE2 / TMPRSS2 expression in capillaries and less in arterioles/venules. The
main coronary arteries were virtually devoid of ACE2 receptor and had only mild intimal inflammation.
Epicardial capillaries had a prominent lympho-monocytic endotheliitis, which was less pronounced in ar-
terioles/venules. The lymphocytic-monocytic infiltrate strongly expressed CD4, CD45, CD68. Peri/epi-
cardial nerves had strong ACE2 expression and lympho-monocytic inflammation. COVID-19 negative
patients showed minimal vascular ACE2 expression and lacked endotheliitis or inflammatory reaction. In-
terpretation ACE2 / TMPRSS2 expression and lymphomonocytic inflammation in COVID-19 disease in-
creases crescentically towards the small vessels suggesting that COVID-19-induced endotheliitis is a small
vessel vasculitis not involving the main coronaries. The inflammatory neuropathy of epicardial nerves in
COVID-19 disease provides further evidence of an angio- and neurotrophic affinity of SARS-COV2 and
might potentially contribute to the understanding of the high prevalence of cardiac complications such
as myocardial injury and arrhythmias in COVID-19. Funding No external funding was necessary for this
study.
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A B S T R A C T
Background: SARS-CoV-2 infection (COVID-19 disease) can induce systemic vascular involvement contribut-
ing to morbidity and mortality. SARS-CoV-2 targets epithelial and endothelial cells through the ACE2 recep-
tor. The anatomical involvement of the coronary tree is not explored yet.
Methods: Cardiac autopsy tissue of the entire coronary tree (main coronary arteries, epicardial arterioles/ven-
ules, epicardial capillaries) and epicardial nerves were analyzed in COVID-19 patients (n = 6). All anatomical
regions were immunohistochemically tested for ACE2, TMPRSS2, CD147, CD45, CD3, CD4, CD8, CD68 and IL-
6. COVID-19 negative patients with cardiovascular disease (n = 3) and influenza A (n = 6) served as controls.
Findings: COVID-19 positive patients showed strong ACE2 / TMPRSS2 expression in capillaries and less in
arterioles/venules. The main coronary arteries were virtually devoid of ACE2 receptor and had only mild inti-
mal inflammation. Epicardial capillaries had a prominent lympho-monocytic endotheliitis, which was less
pronounced in arterioles/venules. The lymphocytic-monocytic infiltrate strongly expressed CD4, CD45,
CD68. Peri/epicardial nerves had strong ACE2 expression and lympho-monocytic inflammation. COVID-19
negative patients showed minimal vascular ACE2 expression and lacked endotheliitis or inflammatory
reaction.
Interpretation: ACE2 / TMPRSS2 expression and lymphomonocytic inflammation in COVID-19 disease
increases crescentically towards the small vessels suggesting that COVID-19-induced endotheliitis is a small
vessel vasculitis not involving the main coronaries. The inflammatory neuropathy of epicardial nerves in
COVID-19 disease provides further evidence of an angio- and neurotrophic affinity of SARS-COV2 and might
potentially contribute to the understanding of the high prevalence of cardiac complications such as myocar-
dial injury and arrhythmias in COVID-19.
Funding: No external funding was necessary for this study.











Coronavirus disease 2019 (COVID-19), caused by the beta corona-
virus SARS-CoV-2, has been spreading dramatically worldwide since
first being reported in Wuhan, Hubei province, China, in December
2019 [1]. While hypoxic respiratory failure due to acute respiratory
distress syndrome (ARDS) is the leading cause of mortality in patients
with COVID-19 infection, hypoxic respiratory failure due to acute
respiratory distress syndrome (ARDS) [2,3], cardiovascular complica-
tions, including myocardial injury with increased troponin levels,
ventricular arrhythmias and heart failure have been reported in 12 to
33% of infected patients [4-6]. COVID-19 is considered a systemic vas-
cular disease affecting multiple organs due to endothelial damage
leading to endotheliitis of the small vessels [7]. To enter cells, SARS-
CoV-2 binds the angiotensin-converting enzyme 2 (ACE2) receptor,
activating the cascade of inflammation [8,9] and potentially causing
severe disease course and eventually fatalities in patients with associ-
ated co-morbidities [10]. An inflammatory olfactory neuropathy and
general neurotropism have been described, frequently resulting in
anosmia (74.8%; range 5.185.6%) and ageusia (81.6%; range
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5.6%88%) [11,12]. However, the involvement of epicardial nerves in
COVID-19 has not been yet studied.
Recently, ACE2 was unequivocally established as the functional
host receptor for SARSCoV-2 [13,14]. Its expression varies between
different organs/tissues, also in association with individual factors
such as age, gender, genetic background, life style, medications and
comorbidities [14]. Zou et al identified organ specific differential vul-
nerability in a large spectrum of organs depending on the ACE2
expression varying from low (such as liver, stomach) and high (such
as heart, respiratory tract) [14]. It has been hypothesized that such
differences could explain the clinical presentation of the disease as
well as individual differences among infected patients [14]. ACE2 is
highly expressed in lung alveolar cells (principally on type II alveolar
cells) and plays a role in lung protection. SARS-CoV-2 binding to
ACE2 receptor deregulates the lung protective pathways, contribut-
ing to viral pathogenicity [15]. Similarly, the ACE2 receptor is signifi-
cantly expressed in endothelial cells of blood vessels, the heart,
pericytes, adipocytes, and neural cells [16]. The expression of ACE2
receptor in small epicardial vessels and peripheral epicardial nerves
however remains elusive.
Transmembrane protease serine type2 (TMPRSS2), belonging to
the type II transmembrane serine protease family, can cleave the
coronavirus spike (S) protein and was demonstrated together with
ACE2 to be crucial for the entry of SARS-CoV-2 into the host cells
[17,18]. Recently, it has been found that ACE2 and TMPRSS2 are
expressed not only in lung tissues, but also in extrapulmonary organs
including heart, kidney, liver, colon, esophagus, brain, gallbladder
and testis, suggesting that SARS-CoV-2 may also affect extrapulmo-
nary organs [19].
The currently accepted concept of the pathogenesis in COVID-19
involves a primarily virus-associated tissue injury followed by an
inflammatory host immune response, which drives hypercytokine-
mia and aggressive inflammation, resulting in endotheliitis, increased
apoptotic activity, thrombotic events and intravascular coagulation
[5,7,9,20,21]. The excessive inflammatory response against SARS-
CoV-2 is thought to define disease severity and death in patients
with COVID-19 [22] and is associated with profound lymphopenia
and substantial mononuclear cell infiltration in the lungs, heart [23],
spleen, lymph nodes, intestine and kidney [24,25] as was observed in
postmortem analyses.
While the lung is the most severely injured organ by SARS-CoV-2
infection in most patients, many other organs are affected as well,
including the heart, liver, kidney, brain, and intestines, resulting in
acute respiratory disease syndrome (71%), acute kidney injury (20%),
cardiac injury (33%), and liver dysfunction (15%), and a need for vaso-
pressor support in up to 67% of patients [2,7,11,26,27]. A recent mul-
ticenter study on a large international cohort of 639 critically ill
patients with confirmed SARS-CoV-2 infection reported that troponin
levels are significantly higher among non survivors than in survivors
(p<0.001), highlighting the importance of myocardial involvement in
COVID-19 [5].
In addition, a meta-analysis of 18 studies and 2984 COVID-19
patients found a significant increase of interleukin-6 (IL-6) in survivor
vs. non-survivors, representing then a marker for potential progres-
sion to critical illness. Indeed, the exaggerated elevation of Interleu-
kin-6 can lead to the so-called “cytokines storm” and may be a driver
behind acute lung injury and ARDS and lead to other tissue damage
progressing to multiorgan failure (MOF) [28,29].
In light of these considerations, the aims of this study were: 1) to
assess the occurrence of endotheliitis in the entire coronary tree
including all anatomical structures from the smallest epicardial ves-
sels through the main coronary artery and to detect possible involve-
ment of epicardial nerves, 2) to characterize morphologically and
immunohistochemically the inflammatory infiltrates, 3) to compare
inflammatory changes in the coronary tree with COVID-19-negative
control autopsies and 4) to correlate the above findings with ACE2,
TMPRSS2, CD147 and interleukin-6 expression in the different ana-
tomical structures including the cardiac nerve conduction system.
2. Methods
2.1. Patients cohort
The entire coronary arterial tree and the surrounding epicardial
soft tissue, including fat and epicardial nerves were examined in
autopsies from six COVID-19 patients at the Department of Pathology
and Molecular Pathology of the University Hospital Zurich, Switzer-
land, during the COVID-19-pandemic between March and April 2020.
Five of six patients of the COVID-19- series (83.3%) had a SARS-CoV-2
Research in Context
Evidence before this study
The currently accepted concept of the pathogenesis in COVID-
19 involves a primarily virus-associated tissue injury followed
by an inflammatory host immune response, which drives
hypercytokinemia and aggressive inflammation, resulting in
endotheliitis, increased apoptotic activity, thrombotic events
and intravascular coagulation. The excessive inflammatory
response against SARS-CoV-2 is thought to define disease
severity and death in patients with COVID-19 and is associated
with profound lymphopenia and substantial mononuclear cell
infiltration in the lungs, heart, spleen, lymph nodes, intestine
and kidney, as was observed in postmortem analyses.
Added value of this study
The results of this study provide evidence that endotheliitis of
small epicardial and intramyocardial vessels poses an impor-
tant pathogenetic mechanism of myocardial injury in COVID-
19 disease. Cardiac inflammatory neuropathy, which has not
been explored yet in the literature, with identical immunophe-
notype as detected in cardiac vessels may contribute to
arrhythmias in COVID-19-patients. The crescentic expansion of
inflammatory reaction towards the small cardiac vessels could
well explain the increased troponin levels with normal epicar-
dial coronary arteries in the absence of acute coronary syn-
drome in patients with COVID-19.
We show in this autopsy cohort, that SARS-CoV-2 infection
results in a small vessel cardiac endotheliitis and cardial neuri-
tis with high level ACE2 and TMPRSS2 expression, which might
explain arrhythmias in COVID-19. Furthermore this study pro-
vides data that COVID-19 disease presents with a different
immunomodulation observed in other RNA viral infections,
such as Influenza A infections as well as in COVID-19 negative
cardiovascular disease.
Implications of all the available evidence
In light of these considerations, the aims of this study were: 1)
to assess the occurrence of endotheliitis in the entire coronary
tree including all anatomical structures from the smallest
epicardial vessels through the main coronary artery and to
detect possible involvement of epicardial nerves: 2) to charac-
terize morphologically and immunohistochemically the inflam-
matory infiltrates. 3) to compare inflammatory changes in the
coronary tree with COVID-19-negative control autopsies and 4)
to correlate the above findings with ACE2, TMPRSS2, CD147
and interleukin-6 expression in the different anatomical struc-
tures including the cardiac nerve conduction system.
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infection confirmed by two positive pharyngeal swabs (RT-PCR SARS-
CoV-2). One patient had a false negative pharyngeal swab, but the
RNA-qRT-PCR examination on paraffin embedded postmortem mate-
rial from the lung because of strong clinical suspect, was positive for
SARS-CoV-2. Four patients were male (4/6, 66.7%) and two female (2/
6, 33.3%) (Range 4581, mean age 68.3 years). All patients had sev-
eral comorbidities (Table 1). The cause of death in all cases was
multi-organ failure and complications of ARDS. One patient had signs
of an acute myocardial infarction three days before death (Patient 4),
but no occlusion of a large vessel could by visualized by coronary
angiography. At the time of admission to the hospital, the electrocar-
diographic monitoring showed sinus tachycardia (heart rate >100/
min) in three of six patients (3/6, 50%) and in one among these also
paroxysmal atrial fibrillation and non-specific repolarization abnor-
malities, in one of these six (1/6, 16.7%), non-specific repolarization
abnormalities, in one these six (1/6, 16.7%) isolated ventricular extra-
systoles (Table 1).
Consent to perform the autopsy was given in all cases and the
institutional review board (Department of Pathology and Molecular
Pathology of the University Hospital Zurich, Switzerland) approved
the study. Ethical aspects on research on autopsy tissue on deceased
patients, postmortem diagnostic and molecular analyses were com-
pleted in accordance with the Swiss Federal Research Regulations
(BASEC Nr. 2020.1316 and 2018.482).
2.2. Control cohorts
Two different control cohorts were selected.
1) Tissues of same anatomical sites from three control autopsies
(patients A-C) were also investigated, which were performed at
our institution about one year before the COVID-19-pandemic
(between May and June 2019) and which showed the same
profile of risk factor observed in the COVID-19-positive cases
(arterial hypertension, diabetes mellitus and obesity). All of them
were middle-aged or elderly patients (range 6282, mean age
73.7 years) and all had at least one comorbidity condition
(Table 2). Two were male (2/3, 66.7%) and one was female (1/3,
33.3%). Two of these patients died due to an acute myocardial
infarction (2/3, 66.7%) and one from aspiration-pneumonia (1/3,
33.3%). None of the control cases had a clinical or laboratory his-
tory of an ongoing viral infection (clinical data of the control
cohort are summarized in Table 2a).
2) A second control autopsy cohort consisted of six patients
(patients D-I) died between 2016 and 2019 from respiratory
insufficiency due to influenza A pneumonia or viral pneumonia.
They were young, middle-aged or elderly patients (range 2285,
mean age 63.5 years). Two were male (2/6, 33.3%) and four
female (4/6, 66.7%). Five of six (5/6, 83.3%) had a laboratory con-
firmed influenza A infection (through nasopharyngeal swab and
RT-PCR with viral RNA detection). At one patient (1/6, 16.7%) the
viral influenza A etiology of the pneumonia was suspected clini-
cally, although the tests of the most common respiratory viruses
(Adenovirus, Influenza A, Coronaviruses 229E, HKU1, NL63,
OC43, Human Metapneumovirus, Bocavirus, Rhinovirus, Parain-
fluenza viruses, respiratory syncytial viruses and Herpes-Simplex
1 und 2) were negative (clinical data of the control cohort are
summarized in Table 2b).
Consent to perform the autopsy was given in all control cases.
2.3. Sample selection and immunohistochemistry
Two or more representative sites of the major coronary arteries as
well as the surrounding epicardial soft tissue were embedded in par-
affin after formalin fixation (FFPE) for further histology in all COVID-
Table 1
Clinico-pathological findings in COVID-19 positive patients at autopsy.
PATIENT AGE (years) GENDER MAIN CLINICAL COMORBIDITIES CARDIAC INVOLVMENT (CLINICAL AND/OR
postmortem diagnosis)
CAUSE OF DEATH
1 70 Male Prostate adenocarcinoma, arterial hyperten-
sion, kidney transplantation due to Alport
syndrome.
Moderately increased T-Troponin,
Histologically focal peracute terminal myo-
cardial ischemia.
DAD/ARDS and pneumonia.
2 77 Female Cutaneous melanoma (stage IIB), arterial
hypertension.
Clinically not known, histologically focal per-
acute terminal myocardial ischemia.
DAD/ARDS, pneumonia
3 79 Male Waldenstr€om’s macroglobulinemia, pulmo-
nary hypertension, obesity (BMI 32.9 kg/
m2).
Moderately increased T-Troponin, histologi-
cally fibrin-thrombi in myocardial
capillaries.
DAD/ARDS, pneumonia
4 58 Female Diabetes mellitus type 2, arterial hyperten-
sion, obesity (BMI 37.8 kg/m2)
Clinically acute myocardial infarction,
strongly increased T-Troponin. At autopsy
no thrombi in coronaries, but histologically
peracute myocardial ischemia.
DAD/ARDS, pneumonia, intestinal ischemia
5 81 Male COPD, arterial hypertension, prostate cancer. Moderately increased T-Troponin, intraven-
tricular thrombosis. Focal peracute myo-
cardial ischemia.
DAD/ARDS, pneumonia
6 45 Male Diabetes mellitus type I, diabetic nephropa-
thy, kidney transplantation due to diabetic
nephropathy, post-transplant, PTLD
Moderately increased T-Troponin, focal pera-
cute myocardial ischemia.intraventricular
thrombosis. Histologically focal peracute
terminal myocardial ischemia
DAD/ARDS, pneumonia
Abbreviations. COPD: chronic obstructive lung disease, PTLD: post transplant lymphoproliferative disease, ARDS: adult respiratory distress syndrome, DAD: diffuse alveolar
damage.
Table 2a
Summary of relevant clinical of the control cohort (COVID-19 negative with cardiovascular diseases).
PATIENT AGE (years) GENDER MAIN COMORBIDITIES CAUSE OF DEATHS
A 82 Male Diabetes mellitus type 2, arterial hypertension, dementia Aspiration-pneumonia
B 62 Male Hypertension, prostate hyperplasia Acute myocardial infarction
C 77 Female Arterial hypertension, diabetes mellitus type 2, obesity (BMI 31.5 kg/m2) Acute myocardial infarction
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19 and all control patients and processed for routine histology such
as hematoxylin-eosin (H&E), elastin van Gieson (EVG) and immuno-
histochemical stains.
All immunohistochemical stains were performed on FFPE tissues
in the Section of Special Technics of the Institute of Pathology and
Molecular Pathology, University Hospital Zurich, with following
clones and pretreatment modalities using the automated Ventana
Benchmark stain system.
Representative slides from each case of the COVID-19-series and
of the control series were stained for CD3 (common T cell marker,
dilution 1:500, Leica, Order Nr. NCL-L-CD3565), CD20 (common B
cell marker, prediluted. Ventana / Roche, Order Nr 7602531), CD45
(Leucocytes Common Antigen, dilution, 1:250, DAKO, Order Nr M
0701), Myeloperoxidase (MPO, a marker for neutrophil granulocytes,
dilution 1:200, NeoMarkers, Order Nr RB-373-A1), CD68 (macro-
phages marker, dilution 1:50, DAKO, Order Nr M0876P), CD4 (marker
of T-helper cells and of macrophages, prediluted, Ventana / Roche,
Order Nr 7904423), CD8 (cytotoxic T cell marker, dilution 1:100,
DAKO, Order Nr M7103), Cleaved Caspase-3 (apoptosis marker, pre-
diluted, Cell Signaling, Order Nr #9661,) and ACE-2 receptor (Angio-
tensin Converting Enzyme 2, entry point of SARS-CoV-2, dilution
1:500, Abcam Limited, Order Nr ab239924), CD31 (vessel endothelial
marker, dilution 1:10, DAKO, Order Nr M0823), TMPRSS2 (CLINE
EPR3861 Abcam, dilution 1:2000), CD147/EMMPRIN (BSG/963, Scy-
Tek Laboratories/RA0428-C, dilution 1:100), IL-6 (10C12, Leica/ NCL-
L-IL6, dilution: 1:50).
Additional stainings for TMPRSS2 (transmembrane protease ser-
ine 2), CD147 (extracellular matrix metalloproteinase inducer, EMM-
PRIN) and IL-6 (interleukin-6) were performed on all cases.
Each immunohistochemistry stain was then evaluated as negative
(-), mild focally positive (+), moderately positive (++) and strongly
positive (+++) independently by two pathologists (U.M. and Z.V),
using a semi-quantitative visual scoring method without knowing
the status of infection (Table 3).
Statistical analysis in the small case number of he cohorts was not
applied.
2.4. Quantitative RT-PCR analysis on paraffin embedded tissue
FFPE tissue from lung (Patient Nr. 2) and from myocardial tissue
(patient Nr 1) underwent PCR based detection of SARS-CoV-2 RNA
testing (Pathology, Cantonal Hospital Liestal, Switzerland), using
probes for the SARS-CoV-2 ORFab1, SARS-CoV-2 S Gene, SARS-CoV-
2 N Gene and a control positive human RNaseP Gene (all reactions
were positive with a value Ct<40).
Lung sample: PCR auf SARS-CoV-2 ORFab1: Positive, Ct: 35.127.,
PCR on SARS-CoV-2 S Gene: Positive, Ct: 32.878. PCR on SARS-CoV-
2 N Gene: Positive, Ct: 33.594., Internal control (PCR on humane RNa-
sePGene): Positive, Ct: 12.7.
Myocardial sample (PCR on SARS-COV-2 ORFab1: Positive. Ct:
35.5, PCR on SARS-COV-2 S Gene: Positive. Ct: 34.3, PCR on SARS-
COV-2 N Gene: Positive. Ct: 35.1, Internal control (PCR on humane
RNaseP Gene): Positive. Ct: 14.6.
2.5. RNA in-situ hybridization on paraffin embedded tissue
In situ hybridization (ISH) for SARS CoV-2 was carried out using a
commercially available probe specific for the viral nucleocapsid gene
according the manufacturers instructions. RNAscope 2.5 LS Probe-V-
nCoV2019-S and RNAscope 2.5 LS Reagent Kit-BROWN; Advanced
Cell Diagnostic [ACD]) on an automated BondRx platform (Leica Bio-
systems). In addition, a human RNA control was applied (in-situ
hybridization assays were performed in the Pathology, Cantonal Hos-
pital Liestal, Switzerland).
2.6. Detection of spike glycoprotein and neurocapsid protein of SARS-
CoV-2 using immunofluorescence
Immunofluorescence (IF) labeling of the spike (S) glycoprotein
and nucleocapsid protein (NP) of SARS-CoV-2 was performed on for-
malin-fixed paraffin embedded (FFPE) myocardial tissue (which was
positive with qRT-PCR) using following clones and antibodies (all
purchased from www.sinobiological.com). We adapted a previously
Table 2b
Clinical characteristics of Influenza A-positive autopsy cohort.
PATIENT AGE (years) GENDER MAIN COMORBIDITIES CAUSE OF DEATHS
Case D 64 Female Trisomy 21, bilateral pneumonia by influenza A. Respiratory insufficiency by severe pneumonia.
Case E 53 Male Bilateral Pneumonia by influenza A infection and superinfection with Aspergillus, Dia-
betes mellitus type 2, DLBCL (16 years before death).
Respiratory insufficiency by DAD/ARDS.
Case F 84 Female Pneumonia by influenza A, Diabetes mellitus type 2, arterial hypertension, chronic
cerebrovascular disease.
Respiratory insufficiency by severe pneumonia.
Case G 73 Male Bilateral pneumonia with ARDS, clinically highly suspicious for viral pneumonia
(although tests of most common respiratory viruses were negative), arterial hyper-
tension, coronary artery disease.
Respiratory insufficiency by DAD/ARDS.
Case H 22 Female Bilateral necrotic pneumonia by influenza A, massive necrosis of the liver of ischemic
genesis.
Multiorgan insufficiency.
Case I 85 Female Pneumonia by influenza A, arterial hypertension, permanent atrial fibrillation. Respiratory insufficiency by severe pneumonia.
Abbreviations: DLBCL diffuse large B-cell lymphoma, ARDS acute respiratory distress syndrome, DAD diffuse alveolar damage.
Table 3
Semi-quantitative method of evaluation of the immunohistochemistry of inflammatory infiltrates in epicardial
tissues.
Negative (-) After careful examination even at greatest magnification (40x) no or just mini-
mally, focal evidence of inflammatory cells.
Mild focally positive (+) Not immediately recognizable inflammatory infiltrates, need to actively search
at great magnification (2040x) or just focal infiltrates.
Moderately positive (++) Almost immediately recognizable inflammatory infiltrates already at middle
magnification (1020x), not just focal or circumscribed but involving sev-
eral contiguous fields.
Strongly positive (+++) Immediately recognizable, clear and diffuse inflammatory infiltrates.
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described procedure for FFPE tissue [30] and used the following
antibodies:
1) Polyclonal rabbit anti-S antibody, Cat#40150-T62-COV2, Dilution
at 1/2000, Pretreatment Ultra CC1 er, visualized with anti-FITC
fluorescent labeling,
2) Monoclonal rabbit anti-NP antibody (labelled with orange tape),
Cat# 40143-R001, Dilution at 1/5000, Pretreatment Ultra CC1 er,
visualized with anti-FITC fluorescent labeling,
3) Monoclonal mouse anti-NP antibody (labelled with purple tape)
Cat#40143-MM05. Dilution at 1/8000, Pretreatment Ultra CC1
mild, visualized with goat anti-mouse Alexa Fluor 488 fluores-
cent labeling.
2.7. Role of funding source
No external funding was necessary for this study. All experiments
were covered by the Internal University Research Funds of the
Department of Pathology and Molecular Pathology University Hospi-
tal Zurich Switzerland, which contributed to study design, data analy-
ses, interpretation and paper drafting.
3. Results
3.1. Inflammatory infiltration in COVID-19-positive and COVID-19-
negative patients
A total of six SARS-CoV-2-positive patients (four males and two
females), three control patients with cardiovascular disease (two
males and one female) and six influenza A/viral pneumonia patients
(four females and two males) were analyzed. Characteristics are sum-
marized in Table 4 (COVID-19-positive patients), Table 5 (COVID-19-
negative patients with cardiovascular diseases), Table 6 (Influenza A
cohort) and graphically illustrated in Fig. 1.
Major coronary arteries: All COVID-19 positive and negative
patients showed atherosclerotic changes in different stages (fibrosis
of intima, intimal xanthoma, fibroatheroma or calcified nodule) in
the major coronary arteries. Both COVID-19 positive and negative
patient tissue samples exhibited mild to moderate lympho-mono-
cytic inflammatory infiltrates, demonstrated by immunohistochemi-
cal stains for CD45+, CD68+ and CD4+ cells. No relevant differences
between COVID-19-positive and COVID-19-negative patients were
found in the inflammation intensity and immunophenotype of
inflammatory cells in the main coronary arteries (Fig. 2a, 2b, Fig. 3a,
3b, Fig. 4a, 4b). Of note, we did not find any typical Kawasaki-like
vasculitis mediated histological changes such as fibrinoid necrosis
and prominent lymphocytic inflammation. Moreover, no aneurysms
were seen.
Arterioles and venules: The arterioles and venules of the COVID-
19-positive patients showed mild to moderate inflammatory infil-
trates rich in lympho-monocytic cells (Fig. 2a, 2b). In contrast,
COVID-19-negative patients (both patients with cardiovascular dis-
ease and influenza A-positive patients) exhibited no or only a mini-
mal inflammatory reaction of lympho-monocytic cells (Fig. 3a, 3b,
Fig 4a, 4b).
Epicardial capillaries: The epicardial capillaries of the COVID-19-
positive patients displayed already on HE-stained sections a mild to
moderate lympho-monocytic inflammation with a perivascular and/
or a subendothelial distribution in five of six cases, while one of the
Table 4
COVID-19 positive cohort: Immunohistological findings in endothelial cells (ACE2)
and endothelial inflammatory cells (CD68, CD45, CD4, CD3, CD8, MPO, Caspase 3) (-
negative, + mild positive, ++ moderate positive, +++ strong positive).
CORONARY Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
ACE2      
CD68 +++ + ++ ++ ++ ++
CD45 ++ ++ ++ ++ ++ +
CD4 ++ ++ ++ ++ ++ ++
CD3 ++  + + + 
CD8 +  + + + 
MPO      
Caspase 3      
ARTERIOLES/VENULES Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
ACE2 + +  + + +
CD68 + + + + + +
CD45 + + + + + +
CD4 + + + ++ ++ +
CD3  +    
CD8  +    
MPO      
Caspase 3      
CAPILLARIES Case1 Case 2 Case 3 Case 4 Case 5 Case 6
ACE2 ++ ++ ++ +++ ++ +++
CD68 +++ ++ ++ +++ ++ +++
CD45 ++ + ++ +++ ++ ++
CD4 ++ + + +++ +++ ++
CD3      +
CD8      
MPO      
Caspase 3      
EPICARDIAL NERVES Case1 Case 2 Case 3 Case 4 Case 5 Case 6
ACE2 + + ++ ++ + ++
CD68 ++ ++ + ++ + ++
CD45 ++ + + ++ + +
CD4 + + + +++ ++ +
CD3      
CD8      
MPO      
Caspase 3      
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cases showed presence of less inflammatory infiltrates (Fig. 2a, 2b
and Fig 5). All COVID-19-negative patients (both patients with car-
diovascular disease and influenza A-positive control groups) showed
virtually no or only very few inflammatory cells in the epicardial
capillaries (Fig. 3a, 3b, Fig 4a, 4b). These HE-findings were corrobo-
rated immunohistochemically: the arterioles/venules as well as the
small capillaries in COVID-19-positive patients (Fig. 2a, 2b and
Fig. 5) showed clearly moderate infiltrates, composed mainly of
CD45+, CD68+ and CD4+ cells, whereas the control-cases showed
only a very mild or none inflammatory change (Fig. 3a, 3b, 4a, 4b).
ACE2 receptors: The endothelium of the major coronary arteries
of both COVID-19-positive and negative patients showed virtually
negative ACE2 receptor staining. In contrast, five of the COVID-19-
positive cases exhibited a mild ACE2 positivity in the venules and
arterioles. Only four of nine COVID-19-negative control patients had
mild ACE2 expression in the venules / arterioles.
ACE2 receptors were diffusely and strongly expressed in the
capillaries and epicardial nerves of all COVID-19-positive cases and
moderately in 3 of 9 COVID-19-negative control patients.
TMPRSS2: The endothelium of the major coronary arteries of both
COVID-19-positive and negative patients showed a mild positive
staining in five of six COVID-19 patients and negative in one patient.
In COVID-19 negative patients with cardiovascular diseases just one
was positive and two were negative, and in Influenza A patients we
found a moderately positive staining in two patients, a mild positivity
in one patient, whereas two were negative and of one no tissue from
major coronary artery was available. In arterioles, venules, capillaries
as well as in epicardial nerves, both COVID-19 positive patients and
negative patients showed positive reaction ranging from mild to
strong, without noteworthy differences among the three cohorts
(Supplementary Table 1, and Supplementary Figures 1,2,3,4).
CD147: There were slightly more positive CD147 inflammatory
cells in the capillaries of COVID-19 patients, however no relevant
expression was find in the control the samples. (Supplementary Table
1, and Supplementary Figures 1,2,3,4).
Interleukin 6 (IL-6): COVID-19 positive patients had more IL-6
positive inflammatory cells especially in the capillaries than control
influenza A and control cardiovascular patients (Supplementary
Table 1, and Supplementary Figures 1,2,3,4).
COVID-19-positive and negative cases all had a very low respec-
tively absent expression of CD3, CD8, CD20, myeloperoxidase and
Caspase-3 (Supplementary Table 1, and Supplementary Figures
2,3,4).
Intramyocardial vessels: Intramyocardial small vessels of all
COVID-19 autopsies showed some degree of endotheliitis too, rang-
ing from mild to moderate intensity, which exhibited the same mor-
phological and immunohistochemical pattern observed in small
epicardial vessels. Here too, a moderate to strong positivity for ACE2
receptor and of TMPRSS2 in endothelial cells of small vessels as well
as in myocardiocytes could be demonstrated in all cases (Fig. 6).
3.2. RNA in-situ hybridization on paraffin embedded tissue
Myocardial sample: No signal was detected neither by antisense
nor by sense probe. Cellular RNA control showed a positive signal.
Table 5
COVID19-negative cohort with cardiovascular diseases:
Immunohistological findings in endothelial cells (ACE2)
and endothelial inflammatory cells (CD68, CD45, CD4, CD3,
CD8, MPO, Caspse 3) (- negative, + mild positive, ++ moder-
ate positive).
CORONARY Case A Case B Case C
ACE2   
CD68 ++ ++ +
CD45 ++ ++ +
CD4 ++ ++ +
CD3  ++ 
CD8  ++ 
MPO   
Caspase 3   
ARTERIOLES/VENULES Case A Case B Case C
ACE2  + 
CD68   
CD45   
CD4   
CD3   
CD8   
MPO   
Caspase 3   
CAPILLARIES Case A Case B Case C
ACE2 + ++ +
CD68   
CD45   
CD4   
CD3   
CD8   
MPO   
Caspase 3   
EPICARDIAL NERVES Case A Case B Case C
ACE2 + + +
CD68  + 
CD45  + 
CD4  + 
CD3   
CD8   
MPO   
Caspase 3   
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3.3. Immunfluorescence labelled immunohistochemistry assays
Immunofluorescence labeled immunohistochemistry demon-
strated scattered reaction products labeling the spikes (S) and the
neurocapsid (NP) components of SARS-CoV-2 in endothelial cells of a
myocardial sample, which was positive in qRT-PCR in FFPE tissue,
corresponding to the indirect viral evidence within the endothelial
cells (Supplementary Fig 5).
4. Discussion
In this study we could demonstrate a crescentic distribution of a
lympho-monocytic inflammatory reaction within the different ana-
tomical regions of the coronary tree in COVID-19 positive patients,
which was strikingly different from the COVID-19 negative controls
including Influenza A infections. Specifically we showed that the vas-
cular inflammatory process in COVID-19 spared the major coronary
Table 6
Influenza A cohort and immunohistological findings in endothelial cells. Immunohis-
tological findings in endothelial cells (ACE2) and endothelial inflammatory cells
(CD68, CD45, CD4, CD3, CD8, MPO, Caspase 3) (- negative, + mild positive, ++ moder-
ate positive, +++ strong positive).
CORONARY Case D Case E Case F Case G Case H Case I
ACE2    NA  
CD68 + +++ + NA  
CD45 ++ ++ + NA  
CD4 ++ ++ + NA + 
CD3  +  NA  
CD8    NA  
MPO    NA  
Caspase 3    NA  
ARTERIOLES/VENULES Case D Case E Case F Case G Case H Case I
ACE2 + + +   
CD68      
CD45 +  +   
CD4  +   + 
CD3      
CD8      
MPO      
Caspase 3    NA  
CAPILLARIES Case D Case E Case F Case G Case H Case I
ACE2 + ++ + + ++ +
CD68  +    +
CD45    +  +
CD4 + + + + + +
CD3      
CD8      
MPO      
Caspase 3    NA  
EPICARDIAL NERVES Case D Case E Case F Case G Case H Case I
ACE2  + + +  +
CD68  +    
CD45      
CD4 + +    
CD3      
CD8      
MPO      
Caspase 3    NA  
Fig. 1. Summary of immunohistological findings (ACE2, CD68, CD45, CD4, CD3, CD8) in the coronary tree and epicardial nerves in COVID-19 positive and COVID-19 negative control
patients. The COVID-19 negative control groups were selected as influenza A positive and a second cohort with cardiovascular diseases.
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arteries and exclusively induced a cardiac small vessel vasculitis
affecting only the cardiac capillaries, arterioles and venules. Addition-
ally we demonstrated a high endothelial ACE2 receptor expression
only in small epicardial vessels/capillaries and in epicardial nerves of
COVID-19 positive individuals, whereas there was no or only very
weak ACE2 receptor expression in major coronary arteries. The endo-
thelia of vasa nervorum and many neural cells and fibroblasts located
in the epineurium were also positive for ACE2. Thus, our findings fur-
ther confirm that COVID-19 disease presents with a different immu-
nomodulation observed in other RNA viral infections, such as
Influenza A infections as well as in COVID-19 negative cardiovascular
disease [31].
We have recently demonstrated systemic endothelial inflam-
mation in COVID-19 patients [7]. In vitro studies of cell lines as
well as immunhistochemichal and electron microscopy analyses
of human renal tissues suggested the presence of SARS-CoV-2
within endothelial cells [7,9,25,32]. Endothelial cell infection with
consecutive inflammatory cell recruitment and endothelial dys-
function may explain impaired microcirculation observed across
vascular beds with vasoconstriction, ischemia and a pro-coagulant
state in COVID-19. Therefore, systemic endotheliitis has been sug-
gested as the major cause of systemic impaired microcirculatory
function observed in different vascular beds in patients with
COVID-19 [7,9,25,32].
Fig. 2. Fig. 2a and 2b: Representative immunostains and H&E sections from COVID-19-positive patients. An endotheliitis of small vessels and a neuritis with prevalence of CD4-pos-
itive and CD68-positive inflammatory cells are demonstrated along with a strong expression of ACE2 receptor. The red (CD31) stains show endothelial cell, the brown reaction prod-
ucts (all other stains) mark positively stained inflammatory cells. Relevant immunostains (CD68, CD45, CD68, ACE2) show a trend being the highest in the capillaries and venules
and less pronounced in the main coronary arteries in a semi-quantitative analysis.
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Here, we demonstrate high ACE2 expression in endothelial cells of
capillaries and epicardial nerves, suggesting that these structures
may be targeted by SARS-CoV-2 due to their enhanced expression of
ACE2 receptor. As a consequence, mainly capillaries and epicardial
nerves develop cardiac inflammatory microangiopathy and neuropa-
thy [33,34]. In one of the myocardial samples, SARS-Cov-2 RNA was
detected with qRT-PCR and we demonstrated most likely indirect
viral effect in scattered endothelial cells on consecutive serial sec-
tions with immunofluorescence labelled immunohistochemistry, fur-
ther supporting the presence of viral induced endothelial damage.
Recently, ACE2 was established as the functional host receptor for
SARSCoV-2 [35], but the role of ACE2 in SARSCoV2 cellular infec-
tion is complex [36] and some studies suggested down-regulation of
ACE2-receptors after virus entry into cells [14-16,35-39].
Importantly, there was virtually no ACE2-receptor expression in
major coronary arteries of both, COVID-19 positive and negative
patients and only weak ACE2-receptor expression in arterioles/ven-
ules of COVID-19 positive patients. Based on our findings, one might
hypothesize that SARS-CoV-2 induces a small vessel endotheliitis in
the heart, because ACE2 receptors exhibit a heterogeneous distribu-
tion increasing toward the small cardiac vessels. Higher ACE expres-
sion in cardiac endothelial cells of small vessels combined with
endothelial inflammation may support the central role of endothelial
cells in COVID-19 disease with poor outcome [40] and could repre-
sent one mechanism of myocardial injury, for which a microangiop-
athy has already been postulated [41]. Caution is needed in
interpreting differential vascular ACE expression between COVID-19-
positive and COVID-19-negative cases. Pre-analytic factors such as
Fig. 3. Fig. 3a and 3b: Representative immunostains and H&E sections from COVID-19-negative control patients with cardiovascular disease. Note the scattered presence of inflam-
matory cells in the control cohort.
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the time between patients’ death, time to tissue sampling and to for-
malin fixation can impact the sensitivity for immunohistochemical
stain for ACE2-receptor. In addition, some very common systemic
disorders (such as diabetes mellitus and hypertension among others),
drugs, age, gender, diet, smoking and ethnicity are known to influ-
ence ACE2 and consequently ACE2-receptor expression [37,38].
To our knowledge, we describe for the first time an inflammatory
neuropathy of the epicardial nerves. This finding could explain
reports of cardiac arrhythmic complications in COVID-19-positive
patients [42]. A study on 138 hospitalized patients from Wuhan,
China, reported an incidence of arrhythmic events, including both
tachyarrhythmia and bradyarrhythmia, of 16.7% overall, of which
44.4% occurred in severe illness and 8.9% in mild cases In our series of
COVID-19 patients, five of the six patients showed cardiac arrhyth-
mias, such as sinus tachycardia, repolarisation abnormalities, ventric-
ular extrasystoles and paroxysmal atrial fibrillation.
To date, no studies on the inflammatory changes and ACE2-recep-
tor expression in epicardial nerves in COVID-19-infection have been
published, although the involvement of central and peripheral ner-
vous system [11,43] and the neuroinvasive potential of coronavi-
ruses (CoVs) has been well documented for most of the CoVs
including SARSCoV-1 and MERSCoV [44]. It is currently unclear
whether the observed cardiac inflammatory neuropathy is a result of
direct viral damage or mediated by a „cytokine storm“. Thus, it is to
Fig. 4. Fig. 4a and 4b: Representative immunostains and H&E sections from COVID-19-negative control patients with influenza A / viral pneumonia infection. Note the scattered
presence of inflammatory cells in the control cohort.
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hypothesize that SARS-CoV-2 targets epicardial nerves through their
elevated ACE2-receptor expression, leading to a cardiac inflamma-
tory neuropathy, which may result in arrhythmic complications.
Of note, the histology of the inflammation was not that of a lym-
phocytic or eosinophilic myocarditis, and cardiac myocytes were not
the target of the inflammatory process. In major coronary arteries
with atherosclerosis, we observed only mild inflammation [45] sug-
gesting that the coronary arteries might not be initially targeted by
the SARS-CoV-2 and the inflammation observed in the major coro-
nary vessels are rather considered as minor reactive changes due to
atherosclerosis. These results could at least partially explain why the
hospitalization for acute coronary syndromes did not increase during
the COVID-19 pandemic [4649]. In our series, all COVID-19-positive
patients had some form of myocardial damage ranging from moder-
ately increased T-troponin without clinical signs to histologically
demonstrable myocardial ischemia (Table 1). These findings are in
concordance with a retrospective study on 112 COVID-19 patients
from Wuhan, which reports increased level of troponin during hospi-
talization in 42 patients (37.5%) but did not demonstrate typical signs
of myocarditis on echocardiography and electrocardiogram [50].
Moreover, our results support the findings of the above mentioned
international prospective observational cohort study in 639 patients
with severe SARS-CoV-2 infection admitted to intensive care units of
whom 97 did not survive and among whom the troponin level was
moderately increased, showing a statistical significant difference
between the survivors group [5]. Myocardial damage is known to
contribute to cardiac dysfunction and arrhythmia and associated
with significantly increased mortality in COVID-19-positive patients
[5,51,52]. However, the pathogenesis of myocardial damage in
COVID-19 is not fully understood [53]. Some patients present with
clinical signs of a myocardial infarction, despite coronary angiogra-
phy visualized no occlusion of major coronary arteries. Heart MRI
analyses rather suggest a peripheral capillary injury, which is consis-
tent with our findings of a microangiopathy due to a small vessel vas-
culitis in COVID-19 [54]. In addition to endothelial damage, multiple
mechanisms appear to contribute, individually or in conjunction
with one another, and they include respiratory failure induced hyp-
oxia, inflammatory cytokine storms, direct viral infiltration and sub-
sequent myocyte death, and myocardial dysfunction from acute
illness [55].
The pathogenetic mechanism in COVID-19 disease is complex and
involves also the activation of several pro-inflammatory factors such
as IL-1, Il-6 [13,56,57]. In addition to ACE2, further receptors such as
TMPRSS2, cathepsins, furin and CD147 (EMMPRIN) play a role in the
initiation and progression of SARS CoV2 infection [13,56]. CD147 has
been shown to be closely involved in cardial inflammation [13,56].
Blocking CD147 can inhibit SARS-Cov-2 replication and thus invasion
of host cells [13,56]. We tested our study cohort for these factors and
could show an increased TMPRSS2 expression in COVID-19 small car-
diac vessels, although the influenza A and cardiovascular control
cases exhibited a similar tendency as well.
CD147 and IL-6 both had a tendency to be more expressed in
inflammatory cells of COVID-19 patients especially in the capillaries,
although the small proportion of positively stained inflammatory
cells most likely do not justify any conclusions in terms of inflamma-
some activation with cardiac involvement as described recently [58].
Direct endothelial viral damage has been documented in several
previous studies using in vivo or in vitro samples [59,60]. Vascular
organoids infected with SARS-CoV-2 were described earlier this year
and the recently published study by Meinhardt et al. demonstrates
endotheliitis and SARS-CoV S protein in the endothelial cells of small
CNS vessels [59,60].
Discrepant viral evidence results between qRT-PCR, ISH and IF/
IHC technologies have been the subject of several recent studies [60-
63]. The presence of current viral load, the phase of disease course as
well as the severity of COVID-19 all have impact on the detection rate
of viral RNA or viral protein in a given sample [60-63].
We showed evidence of SARS-CoV-2 RNA using qRT-PCR in a FFPT
myocardial tissue although the exact anatomical location of viral RNA
evidence could not be proven with ISH methodology, implying an
indirect endothelial damage possibly triggered and enhanced by the
inflammatory cellular reaction rather than the virus itself. On the
other hand, IF labelled reaction products similar as recently described
in central nervous vascular endothelium using the same methodol-
ogy with qRT-PCR and IF labeling on FFPE autopsy tissue as in our
cohort, further support a direct endothelial damage though the
SARS-CoV-2 virus [60,64].
Discrepant SARS-CoV-2 RNA and protein detection can be further
influenced by low level of RNA as was described by Sekulic et al.,
with similar CT values at qRT-PCR as it was the case in our myocardial
sample. [64]. Discrepancies between qRT-PCR and ISH RNA results
(ISH negative and qRT-PCR positive pulmonary samples) were dem-
onstrated on FFPE tissue in a large autopsy study by Massoth et al.
[64]. Another recent study by Ko et al. demonstrated protein spikes
fragments in endothelial cells of cutaneous lesions lacking RNA evi-
dence in ISH suggesting that endothelial incorporated spikes ele-
ments rather than the presence of virions may play the pathogenic
role in COVID-19 endotheliitis [65]
Fig. 6. Intramyocardial small vessels in a COVID-19 patient. a) Small vessel endothelii-
tis with endothelial swelling, denudation, subendothelial lymphocytes and macro-
phages (arrows). b) ACE2 receptor immunohistochemistry. c) CD4 stain. d) CD68 stain.
Fig. 5. Lymphocytic inflammation (arrows) of epicardial nerve (a), venule (b) and cap-
illary (c) from a COVID-19-positive patient. Lympho-monocytic cells infiltrate and
damaged endothelia of small vessels (endotheliitis). Nerves are infiltrated too, not only
in vasa nervorum but also in endonevrium and perineurium. H&E sections.
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A multisystem inflammatory syndrome similar to Kawasaki dis-
ease has been increasingly reported in association with COVID-19 in
children and young adults. This syndrome is rare in adults with just
81 cases reported between 2010 and 2015 [66], known to potentially
affect the main coronary arteries [67], and has been recently reported
in children in association with COVID-19-infection [68-70]. One study
from Bergamo, Italy, reported a 30-fold increased incidence in pediat-
ric population during the pandemic [70,71]. We did not find typical
changes of Kawasaki-disease in the main coronary arteries in our
adult patients. To date, there are only two cases reported in adults in
association with COVID-19-infection [72,73] and further studies are
needed to clarify the association between COVID-19 and Kawasaki-
disease.
Interestingly, the inflammatory infiltrates of the small vessel car-
diac vasculitis in our cohort was composed of macrophages and dom-
inant CD4+ (to less extent CD8+) T-cells, as was also described in a
very recent case report [32]. This phenotype is very similar to those
seen in a moderate antibody-mediated transplant rejection [75]. We
identified endothelial damage in intramyocardial small vessels asso-
ciated with inflammatory infiltrates of lymphocytes and macro-
phages without interstitial hemorrhage, capillary fragmentation,
edema or pyknosis of surrounding myocardial cells. These findings
formally correspond to pAMR2 (pathology Antibody Mediated Reac-
tion grade 2) according to the nomenclature of 2013 ISHLT (Interna-
tional Society for Heart and Lung transplantation) [76]. This
inflammation pattern is different from acute mediated cardiac rejec-
tion, which is characterized by perivascular and/or interstitial infil-
trates, consisting predominantly of CD3, CD4 and CD8-positive
lymphocytes or neutrophils in severe cases but not of macrophages
[76]. The prevalence of macrophages and CD4-positive T-lympho-
cytes without involvement of CD8-positive T-lymphocytes suggests
that COVID-19 disease and antibody-mediated transplant rejection
could share some pathogenic mechanisms, possibly due to inflamma-
tory mediated endothelial damage through a cytokine-storm rather
than a direct viral damage. In particular, these morphological obser-
vations lend further support to the hypothesis that complement acti-
vation could mediate endotheliitis by recruitment of macrophages.
In conclusion, our data provide evidence that endotheliitis of
small epicardial and intramyocardial vessels poses an important
pathogenetic mechanism of myocardial injury in COVID-19 disease.
Cardiac inflammatory neuropathy with identical immunophenotype
as detected in cardiac vessels may contribute to arrhythmias in
COVID-19-patients. The crescentic expansion of inflammatory reac-
tion towards the small cardiac vessels could well explain the
increased troponin levels with normal epicardial coronary arteries in
the absence of acute coronary syndrome in patients with COVID-19.
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